Clinical Trial Update: A Single Center Study for the Treatment of Moderate to Severe Allergic Conjunctivitis (EBI-005-AC-1) [Phase 2]

View source ↗

Summary

This document reports the completion of a Phase 2 single-center clinical trial for moderate to severe allergic conjunctivitis using EBI-005-AC-1. The sponsor is…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Conjunctivitis

Drugs mentioned

• EBI-005-AC-1

Snippet

Sponsor: Eleven Biotherapeutics | Conditions: Allergic Conjunctivitis | Phase 2 | Status: COMPLETED